OBJECTIVES: We conducted phase I and II studies of biweekly @entity1205 and @entity900 with concurrent radiotherapy, followed by consolidation chemotherapy with the same drugs in @entity1 with locally advanced, unresectable @entity1149 ( @entity1149 ). Our objectives were to define the maximum-tolerated dose and dose-limiting @entity137 (DLT) in the phase I study, and to determine the response rate, @entity137 , and survival rate at the recommended dose (RD) in the phase II study. METHODS: @entity1 with unresectable stage IIIA and IIIB @entity1149 were studied. Six to eight cycles of @entity1205 and @entity900 were administered at 2-week intervals. In the phase I study, @entity1 received four dose levels: level 1, @entity1205 / @entity900 =30/40 mg/m2; level 2, 35/40; level 3, 40/40; and level 4, 45/40. Radiotherapy was delivered at a rate of 2 Gy per fraction/day up to a total dose of 60 Gy over the course of 6 weeks, during the first three cycles of chemotherapy. RESULTS: DLT comprised @entity1398 at level 4 in the phase I study (n=15), and level 3 was considered the RD. In the phase II study (n=46), two @entity1 had a complete response (4.3%) and 34 had a partial response (73.9%), for an overall response rate of 78.2% [95% CI (66.3-90.2%)]. The survival rate was 69.1% at 1 year and 39.6% at 2 years, with a median survival time of 19.1 months. @entity1431 , @entity1398 , @entity417 , and @entity1208 were the most common toxic reactions, with Grade > or = 3 reactions occurring at rates of 77, 70, 17, and 8%, respectively. CONCLUSION: Biweekly @entity1205 and @entity900 with concurrent RT was active and well tolerated in @entity1 with unresectable stage III @entity1149 .

Phase I/II trial of biweekly @entity1205 and XXXX with concurrent thoracic radiation for stage III non-small-cell lung cancer.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1208 :: ('MESH:D004935', 'Disease') :: ['radiation esophagitis'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['Leukopenia'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
